<DOC>
	<DOCNO>NCT00849901</DOCNO>
	<brief_summary>The purpose study ass whether duloxetine superior placebo treatment child adolescent major depressive disorder ( MDD )</brief_summary>
	<brief_title>A Study Treatment Children Adolescents With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Outpatient , diagnose major depressive disorder ( MDD ) define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) support Mini International Neuropsychiatric Interview child adolescent ( MINIKID ) . Diagnosis moderate great severity MDD determine Children 's Depression Rating Scale Revised ( CDRSR ) total score great equal 40 screen , randomization Clinical Global Impression Severity ( CGISeverity ) rating great equal 4 screen , randomization . Female patient must test negative pregnancy screen . Judged reliable investigator keep appointment clinical visit , test , procedure require protocol . Has degree understand communicate intelligently investigator study coordinator . Capable swallow study drug whole . It anticipate patient need swallow 6 capsule per day . Patients must venous access sufficient allow blood sample compliant blood draw per protocol . Children site personnel directly affiliate study and/or immediate family . Children Lilly employee employee designate clinical research organization ( CRO ) assist conduct study . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Have current previous diagnosis bipolar disorder , psychotic depression , schizophrenia psychotic disorder , anorexia , bulimia , obsessive compulsive disorder , pervasive development disorder , judge investigator . Have history DSMIVTRdefined substance abuse dependence within past year , exclude caffeine nicotine . Have current primary DSMIVTR Axis I disorder MDD current secondary DSMIVTR Axis I disorder require pharmacologic treatment Have 1 firstdegree relative diagnose bipolar I disorder . Have significant suicide attempt within 1 year screen currently risk suicide opinion investigator . Have weight less 20 kilogram ( kg ) screening . Have lack response 2 adequate treatment trial antidepressant clinically appropriate dose minimum 4 week MDD episode . Have initiate , stop , change type intensity psychotherapy within 6 week prior screen . Have history seizure disorder ( febrile seizure ) . Have history electroconvulsive therapy within 1 year screening . Have treatment monoamine oxidase inhibitor ( MAOI ) within 14 day fluoxetine within 30 day randomization ; potential need use MAOI study within 5 week discontinuation study drug . Have previously enrol , complete , withdrawn study study investigate duloxetine fluoxetine . Have positive urine drug screen substance abuse exclude medication . Are take excluded medication discontinue screen . Have know hypersensitivity duloxetine , fluoxetine , inactive ingredient ; frequent severe allergic reaction multiple medication . Have uncontrolled narrowangle glaucoma . Have acute liver injury severe cirrhosis . Have serious unstable medical illness , psychological condition , clinically significant laboratory electrocardiogram ( ECG ) result , opinion investigator , would compromise participation study likely lead hospitalization . Have abnormal thyroidstimulating hormone concentration . Have initiate discontinue hormone therapy within previous 3 month . Female patient either pregnant , nurse recently give birth . Need use thioridazine study within 5 week discontinuation study drug need use pimozide study .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>